Dr Cathy Burton chaired the “Top Abstracts in Lymphoma” session at BSH 2025. In this episode, she shares with us the highlights from this session. Dr Burton is a Consultant Haematologist at St James’s University Hospital, Leeds, specializing in Lymphoma and Diagnostics. She is heavily engaged in translational research in lymphoma and is Chair of the Hodgkin lymphoma study group, Deputy Chair of the Lymphoma Science study group and a member of the UK Lymphoma Research Group. She has recently been...
Jun 27, 2025•14 min•Ep. 73
Dr Dima El-Sharkawi is a Consultant Haematologist at the Royal Marsden Hospital in Sutton. Her special interests are in CLL, rare leukaemias and lymphomas as well as early phase trials and drug development. She has been an investigator on a number of clinical research studies in these disease groups. She is clinical lead of the Specialist Integrated Haematological Malignancy Diagnostic Services at The Royal Marsden. She is a member of the UK lymphoma research group and CLL trials groups and has ...
Jun 20, 2025•18 min•Ep. 72
Dr Tracey Chan and Dr Jennifer Pinney discuss the Diagnosis and management of monoclonal gammopathy of renal significance Good Practice Paper, published in January 2025.
Jun 13, 2025•23 min•Ep. 71
In this episode, Dr Sridhar Chaganti shares with us the highlights in large B-cell lymphoma from BSH 2025, including real-world experience in the use of bispecific antibodies and the recent NICE approval of Lisocel as second line treatment. Dr Chaganti is a Consultant Haemato-oncologist at the University Hospital in Birmingham, with an interest in lymphomas, ALL, stem cell transplantation and immune effector cell therapies including CART cell therapy. He is the chair of the high-grade lymphoma s...
Jun 06, 2025•18 min•Ep. 70
Presenters: Sean Platton (Consultant Biomedical Scientist) and Peter Baker (Clinical Scientist and the Laboratory Lead for Haemostasis) Measurement of heparin, direct oral anti-coagulants and other non-coumarin anti-coagulants and their effects on haemostasis assays: A British Society for Haematology Guideline This guideline aims to update healthcare professionals working in the UK on the measurement of anti-coagulants (other than coumarins) currently licensed for use in the UK, and their effect...
Jun 03, 2025•18 min•Ep. 69
In this episode, Professor Graham Collins shares with us the highlights in Hodgkin lymphoma from BSH 2025. He takes us through the ECHELON-1 trial, which led to the recent NICE approval of Brentuximab-AVD as a frontline treatment option for advanced stage Hodgkin lymphoma.
May 23, 2025•12 min•Ep. 68
Professor Graham Collins discusses the management of primary mediastinal B-cell lymphoma, from initial treatment considerations to the management of relapsed disease. Professor Collins is a Consultant Haematologist and the lymphoma lead clinician at the Oxford Cancer and Haematology Centre. He has particular interests in Hodgkin and high-grade non-Hodgkin lymphoma and he chairs the national CAR-T panel for lymphoma. Please note that since the recording of this podcast in December 2024, NICE has ...
May 16, 2025•20 min•Ep. 67
Dr Sridhar Chaganti discusses the use of bispecific T-cell engagers (BITE’s) in large B-cell lymphoma. Dr Chaganti is a consultant haematologist at University Hospitals Birmingham NHS Foundation Trust. He has a PhD in cancer studies from the University of Birmingham. His research interest is Epstein–Barr virus (EBV) and lymphomas. His special interests are in haematological malignancies, lymphomas, stem cell transplantation and cellular therapies.
May 09, 2025•31 min•Ep. 66
Dr Nikesh (Nik) Chavda discusses supportive care in lymphoma. Dr Chavda is a haematology consultant at University Hospitals Bristol and Weston, with an interest in B-cell malignancies, cellular therapies and histiocytic disorders.
May 02, 2025•22 min•Ep. 65
Dr Duncan Murray discusses mycosis fungoides and sezary syndrome. Dr Murray completed his PhD at the University of Birmingham, looking at the interaction between the immune system and malignant T cells in skin lymphoma. He finds the interaction between a "good" and "bad" T cell fascinating. He has used multiple single-cell laboratory techniques to tease apart the two populations (including V-beta antibodies, single-cell T-cell receptor (TCR) and ribonucleic acid (RNA) sequencing and mass cytomet...
Apr 25, 2025•36 min•Ep. 64
Dr Matthew Ahearne is a consultant haematologist at University Hospitals of Leicester NHS Trust. His main clinical and research focus is on T-cell lymphomas. Dr Ahearne is Deputy Chair of the National Cancer Research Institute (NCRI) T-cell lymphoma working group and an NCRI Lymphoma Science sub-group member.
Apr 23, 2025•35 min•Ep. 63
Dr Sridhar Chaganti discusses the current management of post-transplant lymphoproliferative disorder (PTLD), including subtypes, prognostic factors and the current treatment options. He explores the role of immunotherapy, cytotoxic agents and the emerging field of cellular therapies in this group of patients. Dr Chaganti is a consultant haematologist at University Hospitals Birmingham NHS Foundation Trust. He has a PhD in cancer studies from the University of Birmingham. His research interest is...
Apr 11, 2025•29 min•Ep. 62
Dr Aisling Barrett discusses the guideline on Assessment of fitness for bleomycin use and management of bleomycin pulmonary toxicity in patients with classical Hodgkin lymphoma
Feb 21, 2025•13 min•Ep. 61
Professor Martin Kaiser & Dr Ceri Bygrave discuss the Advanced imaging for earlier diagnosis and morbidity prevention in multiple myeloma guideline.
Feb 21, 2025•40 min•Ep. 60
Professor Martin Kaiser and Dr Matthew Jenner discuss the BSH Good Practice Paper for the diagnosis and initial treatment of transplant-eligible high-risk myeloma patients, published in July 2024.
Feb 14, 2025•36 min•Ep. 59
Nov 06, 2024•12 min•Ep. 58
Dr Amma Kyei Mensah, Dr Sarah Nicolle and Dr Farrukh Shah discuss the BSH Guideline for the management of conception and pregnancy in thalassaemia syndromes, published in 2024.
Oct 14, 2024•53 min•Ep. 57
Professor Guy Pratt discusses the investigation, diagnosis and management of smouldering myeloma. This podcast is based on the British Society for Haematology’s 2024 Good Practice Paper, Diagnosis and management of smouldering myeloma.
Sep 24, 2024•19 min•Ep. 56
This guidance update from the BSH is focussed primarily on non-surgical invasive procedures, simply termed ‘procedures’ in this document, with the primary objective of giving pragmatic advice where evidence is limited. This guidance also aims to reduce unnecessary laboratory testing, inappropriate use of blood products and unnecessary delays in therapeutic procedures. 1 It should be read in conjunction with the Interventional Radiology (IR) procedure bleeding risk guidance produced by the Britis...
Jul 22, 2024•48 min•Ep. 55
Podcast by Dr Donal P. McLornan on The management of myelofibrosis.
Jul 22, 2024•26 min•Ep. 54
Since the last version of the BCSH (British Committee for Standards in Haematology) Guidelines for Specification, implementation and management of Information Technology (IT) in hospital transfusion laboratories was published1 there has been continued development in IT applications for use in transfusion medicine. IT has made a major contribution to blood safety throughout the transfusion chain, and there is increasing use of IT solutions to allow laboratories to meet some of the challenges of t...
Jul 12, 2024•14 min•Ep. 53
May 14, 2024•32 min•Ep. 52
A podcast recording by Dr Deepa J. Arachchillage on the guideline: Diagnosis and management of heparin-induced thrombocytopenia: Third edition.
Apr 19, 2024•26 min•Ep. 51
The objective of this podcast presented by Kim Linton and Renata Walewska is to provide healthcare professionals with clear guidance on the diagnosis and management of patients with marginal zone lymphoma (MZL).
Apr 08, 2024•30 min•Ep. 50
Guideline on the Investigation and management of a raised serum ferritin: A podcast recording of a conversation between Dr Jenny Tam and Dr Wayne Thomas.
Apr 04, 2024•17 min•Ep. 49
Antenatal screening/testing of pregnant women should be carried out according to the guidelines of the National Health Service (NHS) Sickle Cell and Thalassaemia Screening Programme. Newborn screening and, when necessary, follow-up testing and referral, should be carried out according to the guidelines of the NHS Sickle Cell and Thalassaemia Screening Programme. All babies under 1 year of age arriving in the United Kingdom should be offered screening for sickle cell disease (SCD). Preoperative s...
Nov 29, 2023•29 min•Ep. 48
The objective of this guideline is to provide healthcare professionals with clear guidance on the diagnosis and management of patients with mantle cell lymphoma.
Nov 21, 2023•12 min•Ep. 47
This Good Practice Paper podcast provides recommendations for the diagnosis, risk stratification and management of the monoclonal gammopathy of undetermined significance (MGUS). It describes the recently recognised entity of the monoclonal gammopathy of clinical significance (MGCS), and recommends how it should be managed. The potential for targeted population screening for MGUS is also discussed.
Aug 02, 2023•20 min•Ep. 46
Jul 12, 2023•19 min•Ep. 45
Haematological management of major haemorrhage: A podcast recording of a conversation between Prof Simon Stanworth and Dr Heidi Doughty.
Jun 07, 2023•21 min•Ep. 44
